The estimated Net Worth of Elan Ezickson is at least 859 千$ dollars as of 6 February 2023. Mr. Ezickson owns over 750 units of Alaunos Therapeutics Inc stock worth over 4,872$ and over the last 15 years he sold ZIOP stock worth over 641,206$. In addition, he makes 212,562$ as Independent Director at Alaunos Therapeutics Inc.
Elan has made over 7 trades of the Alaunos Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 750 units of ZIOP stock worth 4,920$ on 6 February 2023.
The largest trade he's ever made was selling 10,000 units of Alaunos Therapeutics Inc stock on 10 June 2011 worth over 187,300$. On average, Elan trades about 1,620 units every 174 days since 2010. As of 6 February 2023 he still owns at least 5,600 units of Alaunos Therapeutics Inc stock.
You can see the complete history of Mr. Ezickson stock trades at the bottom of the page.
Elan Z. Ezickson J.D. serves as Independent Director of the Company. Mr. Ezickson has served as a member of our board since September 2018. Mr. Ezickson served as Chief Operating Officer & Head of Corporate Development for Scholar Rock Holding Corporation from August 2014 until his retirement in December 2018. Prior to Scholar Rock, Mr. Ezickson served as Executive Vice President and Chief Operating Officer of Aveo Pharmaceuticals, Inc., where he worked from 2003 to July 2013. Previously, Mr. Ezickson worked at Biogen Inc. in roles of increasing responsibility, including serving as the President of Biogen Canada, Program Executive and Associate General Counsel. Since December 2019, Mr. Ezickson has served on the board of directors of Marinus Pharmaceuticals, Inc., a publicly-held company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders. Mr. Ezickson holds a B.A. in Political Science from Yale University and a J.D. from the Columbia University School of Law. The board believes that Mr. Ezickson’s deep operating and management experience at several leading life science companies, as well as his legal expertise and operational experience, qualifies him to serve on the board.
As the Independent Director of Alaunos Therapeutics Inc, the total compensation of Elan Ezickson at Alaunos Therapeutics Inc is 212,562$. There are 9 executives at Alaunos Therapeutics Inc getting paid more, with Laurence Cooper having the highest compensation of 3,317,570$.
Elan Ezickson is 56, he's been the Independent Director of Alaunos Therapeutics Inc since 2018. There are 7 older and 10 younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.
Elan's mailing address filed with the SEC is 5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD RD, RADNOR, PA, 19087.
Over the last 19 years, insiders at Alaunos Therapeutics Inc have traded over 2,792,771$ worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth 39,823,909$ . The most active insiders traders include Randal J Kirk、Randal Jintrexon Corp Kirk、Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of 152,086$. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth 25,568$.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include: